first member of a new chemical class of AChE inhibitors, Introduction the piperidines [6, 7] . It has a high selectivity for AChE in the central nervous system (CNS) and is clinically effective Although Alzheimer's disease is one of the most common forms of dementia in the elderly, its aetiology remains at a dose of 5 mg day −1 [8] [9] [10] [11] [12] . Clinical trial results have demonstrated a statistically significant improvement in poorly understood. Nonetheless, it is generally recognized that cholinergic pathways in the cerebral cortex and basal cognitive and global function at both 5 and 10 mg day −1 doses [10] [11] [12] . Donepezil is well tolerated, occasionally forebrain are compromised in these patients and that the resulting cholinergic deficit contributes to the cognitive producing transient gastrointestinal symptoms such as abdominal pain, nausea and vomiting, which usually resolve impairment that characterizes the disease [1, 2] . In support of this hypothesis, the cholinesterase inhibitors have demonwith continued drug administration and without the need for dose adjustment. Unlike physostigmine and tacrine, there strated the most promising results of any class of drugs for the symptomatic treatment of Alzheimer's disease [3] . The is no evidence that donepezil produces cardiovascular sideeffects or has any effect on hepatic enzymes [12] . rationale for using these agents is that they restore the physiological effect of acetylcholine (ACh) by increasing its Digoxin is prescribed extensively to elderly patients for the treatment of atrial fibrillation and congestive heart levels in surviving cholinergic synapses within the cerebral cortex [4] . In addition, evidence suggests that acetylcholinesfailure. It has a narrow therapeutic index and optimal drug dosing is essential. Digoxin is eliminated from the body terase (AChE) may be involved in the regulation of nerve growth as well as in the modulation of functional cholinergic predominantly by renal excretion [13] , a process which is known to be compromised by ageing [14] . activity [5] . This finding emphasizes the potential importance of developing new and specific AChE inhibitors for the The co-administration of any drug that alters the metabolism or elimination of digoxin could thus result in treatment of Alzheimer's disease. Donepezil HCl (also known as E2020 or AriceptA, the digoxin toxicity or, conversely, sub-therapeutic plasma levels of digoxin, leading to the re-emergence of underlying registered trademark of Eisai Co. Ltd, Tokyo, Japan) is the cardiovascular symptoms. include reduction in the bioavailability of digoxin as a result of interactions with antacid gels, antibiotics and All volunteers were screened by medical history, ECG plus laboratory and physical examinations ≤2 weeks prior kaolin pectate; altered steady-state serum levels when co-administered with quinidine; and altered renal excretion to the start of the study. During the course of the study, subjects were not allowed to consume caffeine-containing when administered in combination with potassium-sparing diuretics.
food or drinks or to sunbathe, and physical exercise was limited to normal walking. Over-the-counter products were As Alzheimer's disease is a condition that is more prevalent in later life, a significant percentage of Alzheimer's disease discontinued from 72 h prior to admission into the trial until the end of the study. patients will be taking digoxin for the treatment of concomitant cardiac conditions. Hence, an awareness of the For each treatment period, subjects were admitted to the study site on the evening of day 0, at least 12 h prior to potential for a drug-drug interaction is critically important. The present study was designed to determine if either a drug administration. Subjects were fasted overnight (8 h), prior to receiving their first dose of medication on the pharmacokinetic or pharmacodynamic interaction could result following the concurrent administration of single doses morning of day 1. of donepezil HCl and digoxin. Plasma was removed, transferred into polypropylene tubes Laboratories, Lincoln, Nebraska, USA. All subjects provided and stored upright at −20°C until analysis. written informed consent prior to participation in any study Plasma donepezil concentrations were measured using a activities.
Sample collection and analysis
specific high-performance liquid chromatography (HPLC) Eligibility for entry into the study was assessed at a method with UV detection, with a lower detection limit of screening visit, which was conducted a maximum of 14 days 2.0 ng ml −1 [16] . Digoxin concentrations were determined prior to administration of the first dose of trial medication.
by radioimmunoassay using the Becton Dickenson Digoxin Subjects with evidence of significant hepatic, gastrointestinal, Solid Phase Component System TM . The assay was based on renal, respiratory, endocrine, haematological, neurological, the inverse relationship between the competitive binding of psychiatric or cardiovascular system abnormalities were [
125 I]-labelled digoxin and unlabelled digoxin by digoxinspecifically excluded from the study, as were those who had specific antibodies immobilized on the wall of polypropylene a known or suspected history of alcohol or drug misuse or sample tubes. This method had upper and lower detection a positive urine drug screen. None of the subjects had limits of 2.5 and 0.1 ng ml −1 , respectively. donated blood or had received investigational or prescription medications within 1 month of study enrolment.
Subjects were healthy, Caucasian, male volunteers Pharmacokinetic assessments between 18 and 45 years of age whose body weights, ranging from 60 to 85 kg, were within 20% of ideal weight, Characterization of donepezil and digoxin pharmacokinetics for each treatment group was conducted using plasma drug based on the Metropolitan Insurance Company Height and Weight Tables (1983). concentration data from samples collected over a 120-h period following drug administration. All volunteers who received test medication and who had analytical samples Protocol collected were evaluated. The donepezil and digoxin plasma concentrations from This was an open-label, randomized, single-dose, threeperiod crossover study. Subjects were randomized to a each subject were plotted as log concentration versus time.
The pharmacokinetic parameters were estimated by a nonparticular treatment according to a computer-generated randomization schedule. The three treatments administered compartmental method for both drugs. The peak plasma concentration (C max ) of each drug, time of occurrence of in this study were: (1) donepezil HCl, 5 mg tablet, (2) digoxin, 0.25 mg tablet (LanoxinA, Burroughs Wellcome C max (t max ) and the terminal disposition phase for each subject were derived from inspection of log concentrationLaboratories), or (3) a combination of donepezil HCl (5 mg ) and digoxin (0.25 mg ). During each treatment period, time curves. The terminal disposition rate constant (l z ) was estimated as −2.303 times the slope of the best-fit linear subjects received a single oral dose of either donepezil or digoxin alone, or both drugs in combination. Each treatment regression line of the terminal phase, the terminal half-life (t D ) was calculated as 0.693/l z and the area under the plasma period was 6 days in duration (drug administration plus blood sampling ), followed by a 2-week, drug-free washout concentration-time curve from 0 to 120 h (AUC (0-120) ) was estimated using the trapezoidal rule. The area under the period. The dose of donepezil was chosen based upon clinical efficacy studies conducted in the USA, and the dose plasma concentration-time curve extrapolated to infinity (AUC (0-2 ) ) was calculated as AUC (0-120) plus the last of digoxin used is the recommended clinical dose provided by the Physicians' Desk Reference. measured concentration divided by l z .
Safety assessments donepezil treatment groups (donepezil alone and in combination with digoxin) are shown in Figure 1 . All adverse events reported spontaneously by the subjects and/or observed or elicited during physical examination Pharmacokinetics of digoxin were documented together with times of onset and cessation, plus assessment of severity and causality. Vital signs were
No statistically significant differences in digoxin pharmacomonitored at regular intervals during the in-house portion kinetic parameters were observed when digoxin administered of each treatment period. Laboratory evaluations were alone was compared with digoxin administered with conducted at the start of each treatment period. Telemetry donepezil. As shown in Table 2 , the values of C max were monitoring (lead II ECG) began 1 h prior to drug identical for both groups (0.8±0.1 ng ml −1 ), and the values administration and continued for 24 h after each dose.
for t max , AUC (0-120) , AUC (0-2 ) and t D differed only Lead II rhythm strips were generated prior to drug marginally (Table 2 ). In addition, there were no significant administration and 1, 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postsequence or period effects observed between treatment dose. Heart rate, PR interval, QRS duration and QT groups. Mean plasma concentration-time profiles of both interval were recorded. digoxin treatment groups (digoxin alone and in combination with donepezil) are shown in Figure 2 .
Statistical analysis
Telemetry An analysis of variance model (ANOVA), accounting for the effects of treatment, period, sequence and subject, was
Increases and decreases in heart rate (bpm) and duration (s) used to compare the pharmacokinetic parameters derived of the PR and QRS intervals were observed for all of the during the three treatment periods. The type III sum of subjects during the 24 h of lead II ECG monitoring squares for all model effects was used to determine statistical following drug administration. However, these changes were significance at the 0.05 level.
typically small (±2%) and there were no discernible trends among the treatment groups which would relate these parameters to a particular time course or to a treatment Results effect. The observed fluctuations were judged by the investigators not to be clinically relevant. Subjects
The study population comprised 12 healthy, Caucasian, Vital signs male volunteers with a mean age of 28.3 years (range 19-44
The mean changes from baseline for radial pulse rate, systolic years). Their heights ranged from 171 to 191 cm (mean and diastolic blood pressure for each treatment group indicate 179.9 cm) and their body weights from 66.5 to 85.0 kg (mean 77.6 kg ). Each of the 12 subjects completed the study without incident.
Pharmacokinetics of donepezil
No statistically significant differences in donepezil pharmacokinetic parameters were observed when donepezil administered alone was compared with donepezil administered concurrently with digoxin. As shown in Table 1 , the values for t max and C max were identical for both treatment groups (4.5±0.4 h and 6.3±0.3 ng ml −1 , respectively), and the values for AUC (0-120) , AUC (0-2 ) and t D differed only marginally (Table 1 ). In addition, there were no significant groups. Mean plasma concentration-time profiles of both No statistically significant differences in donepezil or digoxin pharmacokinetic parameters (C max , t max , that the co-administration of donepezil and digoxin does AUC (0-120) , AUC (0-2 ) or t D ) were observed when the not influence blood pressure or pulse rate to a greater degree pharmacokinetic profiles of these drugs administered alone than the administration of donepezil or digoxin alone.
were compared with the profiles of the drugs administered in combination. In addition, no clinically significant changes in cardiac conduction were observed during the 24 h of Adverse events post-drug telemetry monitoring (lead II ECG), nor were No serious adverse events were reported during this study.
there any clinically significant changes in vital signs during Only five of the 12 subjects enrolled in this study reported the course of the study. These data demonstrate that no any adverse events during the course of this trial. These pharmacokinetic interaction follows concurrent single-dose, events included fatigue, headache, diarrhoea, lightoral adminstration of these drugs. In addition, the absence headedness and vivid dreams. All reported adverse events of an interaction following single-dose administration sugwere mild to moderate in severity.
gests the same lack of effect on the plasma levels of these drugs at steady state.
Discussion
We acknowledge the efforts of Dr James Kisicki, Harris The primary objective of this study was to examine the Laboratories Inc, 624 Peach Street, Box 80827, Lincoln, pharmacokinetics of donepezil and digoxin separately, and NE 68501, USA, who conducted this clinical trial, and the in combination following administration of single oral doses.
Institutional Review Board of Harris Laboratories, who The basis for this approach was to determine if a reviewed and approved the study and protocol. pharmacokinetic interaction existed between these two drugs and also to determine if their concurrent administration produced any clinically significant changes in cardiac References parameters ( lead II ECG). 
